A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals

Journal of Hypertension

Volumn 29, Issue 3, 2011, Pages 509-519

  Brugts, Jasper J ^a   Isaacs, Aaron ^b   De Maat, Moniek P M ^b   Boersma, Eric ^a   Van Duijn, Cock M ^b   Akkerhuis, K Martijn ^a   Uitterlinden, Andre G ^a,b   Witteman, Jacqueline C M ^a   Cambien, Francois ^c   Ceconi, Claudio ^d   Remme, Willem ^e   Bertrand, Michel ^f   Ninomiya, Toshiharu ^g   Harrap, Stephen ^h   Chalmers, John ^g   MacMahon, Stephen ^g   Fox, Kim ⁱ   Ferrari, Roberto ^d   Simoons, Maarten L ^a   Danser, A H Jan ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Department of Genetic Epidemiology ^*  (Netherlands)

^c INSERM   (France)

^d UNIVERSITY OF FERRARA   (Italy)

^e STICARES Cardiovascular Research   (Netherlands)

^f Lille Heart Institute   (France)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitors; gene; hypertension; PERGENE; pharmacogenetics; polymorphism; PROGRESS; renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSINOGEN; BRADYKININ; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; KALLIKREIN; PERINDOPRIL; PRORENIN RECEPTOR; RENIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR DISEASE;

EID: 79951673075     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328341d117     Document Type: Article

References (40)

1. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press; 1990. pp. 81-100.
2. Pickering G. High blood-pressure evident cause: essential hypertension. BMJ 1965; 5469:1021-1026.
3. Inagami T. The renin-angiotensin system. Essays Biochem 1994; 28:147-164.
4. Brugts JJ, den Uil CA, Danser AHJ, Boersma E. The renin-angiotensin- aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 2008; 112:303-312.
5. Agerholm-Larsen B, Nordestgaard BG, Tybjærg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20:484-492. (Pubitemid 30086107)
6. Danser AHJ, Schalekamp MADH, Bax WA, van den Brink AM, Saxena PR, Riegger GA, Schunkert H. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387-1388.
7. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2003; 23:1269-1275. (Pubitemid 36871283)
8. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
9. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JCM. ACE polymorphisms. Circ Res 2006; 98:1123-1133. (Pubitemid 43948098)
10. Niu W, Qi Y, Hou S, Zhai X, Zhou W, Qiu C. Haplotype-based association of the renin-angiotensin-aldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan study. J Hypertens 2009; 27:1384-1391.
11. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens 2009; 22:954-957.
12. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61:1461-1468. (Pubitemid 47228610)
13. Harrap S, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J, et al., PROGRESS Collaborative Group. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003; 42:297-303. (Pubitemid 37093476)
14. The EUROPA trial investigators. The European Trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
15. Brugts JJ, de Maat MPM, Boersma E, Witteman JCM, van Duijn C, Uitterlinden AG, et al. The Rationale and Design of the Perindopril Genetic Association Study: a pharmacogenetic analysis of ACE-inhibitor therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2009; 23:171-181.
16. Gomma AH, Fox KM, for the EUROPA investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15:169-179. (Pubitemid 32917573)
17. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
18. Nederhand RJ, Droog S, Kluft C, Simoons ML, de Maat MP. Logistics and quality control for DNA sampling in large mult-center studies. J Thromb Haemost 2003; 1:987-991.
19. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
20. De Bakker PIW, Yelensky R, Peer I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nature Genet 2005; 37:1217-1223. (Pubitemid 41568704)
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. v7th report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. Hypertension 2003; 42: 1206-1252.
22. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics 1994; 138:963-971. (Pubitemid 24337818)
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434. (Pubitemid 34112296)
24. HofmanA,Grobbee DE, de Jong PT, van den Ouwenland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7:403-422.
25. Abdollahi MR, Huang S, Rodriguez S, Guthrie PA, Smith GD, Ebrahim S, et al. Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women's Heart and Health Study (BWHHS). Dis Markers 2008; 24:11-17. (Pubitemid 350174566)
26. Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther 2007; 113:607-618. (Pubitemid 46365959)
27. Danser AHJ, Derkx FHM, Hense HW, Jeunemaître X, Riegger GA, Schunkert H. Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 1998; 16:1879-1883. (Pubitemid 29002363)
28. Hirose T, Hashimoto M, Totsune K, Metoki H, Asayama K, Kikuya M, et al. Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: the Ohasama study. Am J Hypertens 2009; 22:294-299.
29. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, BurckléCA, et al. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25:2441-2453. (Pubitemid 350060383)
30. Batenburg WW, Danser AHJ. The (pro)renin receptor: a new addition to the renin-angiotensin system? Eur J Pharmacol 2008; 585:320-324.
31. Niua W, Yue Qic M, Houe S, et al. Haplotype-based association of the renin-angiotensinaldosterone system genes polymorphisms with essential hypertension among Han Chinese: the Fangshan study. J Hypertens 27:1384-1391.
32. Cruciat CM, Ohkwara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, et al. Requirement of prorenin receptor and vacuolar H\+-ATPase-mediated acidification for Wnt signaling. Science 2010; 327:459-465; doi: 10.1126/science.1179802.
33. Batenburg WW, de Bruin RJA, van Gool JM, Müller DN, Bader M, Nguyen G, Danser AHJ. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28:1151-1157.
34. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005; 46:1069-1076. (Pubitemid 41533004)
35. Fisher ND, Danser AHJ, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117:3199-3205.
36. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52:130-136.
37. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339:1285-1292. (Pubitemid 28496194)
38. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) Study. Circulation 2005; 111:3374-3383. (Pubitemid 40923390)
39. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009; 30:1385-1394.
40. Brugts JJ, Isaacs A, Boersma E, van Duijn CM, Uitterlinden AG, Remme W, et al. Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J 2010; 31:1854-1864.